Page 15

Revista-Chilena-de-Infectologia-3-2017

Antimicrobianos Artículo Original www.sochinf.cl 211 Wade P, Howard P. Identifying best practices across three countries: hospital antimicrobial stewardship in the United Kingdom, France, and the United States. Clin Infect Dis 2014; 59 Suppl 3: S170-8. 13.- Cataño J. The economic and ecologic impact of infectious diseases specialists in hospitals. Acta Med Col 2008; 33: 58-62. 14.- Cataño J, Castaño O. Evaluation of the impact of a program of epidemiological surveillance in consumption of antibiotics and flora in a third level clinic. Infectio 2009; 13: 6-13. 15.- Pallares C J, Martínez E. Implementation of a regulated antibiotic use program in two medical-surgical intensive units care in a third level mayor teaching hospital in Colombia. Infectio 2012; 16 (4): 192-8. 16.- Pallares C J, Martínez E. Mortality risk factors associated with healthcare infections in a tertiary level university hospital in Colombia. Biomédica 2014; 34 (Suppl 1): 148-55. 17.- Barlam T F, Cosgrove S E, Abbo L M, MacDougall C, Schuetz A N, Septimus E J, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15; 62 (10): e51-77. 18.- CLSI. Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014. 19.- Horan T C, Andrus M, Dudeck M A. CDC/ NHSN surveillance definition of health careassociated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32. 20.- Huttner B, Harbarth S, Nathwani D. ESCMID Study Group for Antibiotic Policies (ESGAP). Success stories of implementation of antimicrobial stewardship: a narrative review. Clin Microbiol Infect 2014; 20: 954-62. 21.- Pulcini C, Mainardi J L. Antimicrobial stewardship: an international emergency. Clin Microbiol Infect 2014; 20: 947-8. 22.- Wagner B, Filice G A, Drekonja D, Greer N, MacDonald R, Rutks I, et al. Antimicrobial stewardship programs in inpatient hospital settings: a systematic review. Infect Control Hosp Epidemiol 2014; 35: 1209-28. 23.- Pena C, Guzmán A, Suárez C, Domínguez M A, Tubau F, Pujol M, et al. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenemresistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 2007; 51 (6): 1967-71. 24.- Paterson D L, Ko W C, Von Gottberg A, Mohapatra S, Casellas J M, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum, beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140 (1): 26-32. 25.- Cassier P, Lallechère S, Aho S, Astruc K, Neuwirth C, Piroth L, et al. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M beta-lactamaseproducing E. coli: a case-control study in a French teaching hospital. Clin Microbiol Infect 2011; 17(11): 1746-51. 26.- Dinubile M J, Friedland I, Chan C Y, Moltyl M R, Giezek H, Shiveprakash M, et al. Bowel colonization with resistant gram negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24 (7): 443-9. 27.- Vesga O, Agudelo M, Salazar B, Rodríguez C A, Zuluaga A F. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010; 54: 3271-79. 28.- Rodríguez C A, Agudelo M, Cataño J C, Zuluaga A, Vesga O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J Infect 2009; 59: 277-80. Rev Chilena Infectol 2017; 34 (3): 205-211


Revista-Chilena-de-Infectologia-3-2017
To see the actual publication please follow the link above